-
Certolizumab pegol, sold
under the
brand name Cimzia, is a
biopharmaceutical medication for the
treatment of Crohn's disease,
rheumatoid arthritis, psoriatic...
-
cause confusion in
prescribing and
dispensing and
should be avoided.
Certolizumab pegol, etanercept,
golimumab and
infliximab are alternatives, including...
- system. The use of anti-TNF
monoclonal antibodies such as
adalimumab and
certolizumab have been
approved for
Crohn disease. Andreozzi, Laura; Giannetti, Arianna;...
-
monoclonal antibodies (MAbs) (infliximab, adalimumab, golimumab, and
certolizumab pegol) and one
recombinant TNF-α
decoy receptor, etanercept, have been...
-
including Keppra (levetiracetam),
Xyzal (levocetirizine), and
Cimzia (
certolizumab pegol),
which arrived through the
acquisition of Celltech. At the end...
- remission, with FDA-approved
agents including infliximab, adalimumab, and
certolizumab pegol. It
blocks the
inflammatory protein TNF and
induces cell death...
- methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, TNF
inhibitors (
certolizumab, adalimumab,
infliximab and etanercept), abatacept, anakinra, and auranofin...
-
Sonermin Tasonfermin TNF (TNFα)
Ungrouped Antibodies:
Adalimumab Afelimomab Certolizumab pegol Golimumab Infliximab Nerelimomab Ozoralizumab Remtolumab Placulumab...
- it is in development. For example, CDP870 was UCB's
company code for
certolizumab pegol; UCB
later chose "Cimzia" as its
trade name. Many of
these codes...
- spondylitis. TNFi drugs, such as etanercept, infliximab, adalimumab,
certolizumab, and golimumab,
target the
inflammatory cytokine tumor necrosis factor-alpha...
